Clinical Trial Update: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ritonavir-boosted danoprevir with RO5024048 in null responders or treatment-naïve chronic hepatitis C patients with compensated cirrhos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• RO5024048
• Ritonavir-boosted danoprevir (danoprevir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED